BioCryst resumes flu trial
Executive Summary
BioCryst resumes enrollment in a 1,300-patient Phase III trial for its neuraminidase inhibitor peramivir after discussing additional monitoring with FDA; the trial was stopped in early 2001. Johnson & Johnson returned rights to the influenza drug to BioCryst at that time (1"The Pink Sheet" June 11, 2001, p. 19)...
You may also be interested in...
J&J's Revamped R&D Will Release First Drug In 2004, Diabetic Likely Choice
Johnson & Johnson's re-engineered research and development program will release its first product in 2004, most likely in the diabetes area, R&D Pharmaceuticals Chairman Per Peterson, MD/PhD, indicated.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.